scholarly journals What matters to patients and clinicians when discussing the impact of cancer medicines on health-related quality of life? Consensus-based mixed methods approach in prostate cancer

2021 ◽  
Author(s):  
Emma Dunlop ◽  
Aimee Ferguson ◽  
Tanja Mueller ◽  
Kelly Baillie ◽  
Julie Clarke ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Prostate Cancer ◽  
Mixed Methods ◽  
Nominal Group ◽  
Health Related Quality ◽  
Related Quality ◽  
Health Related ◽  
The Impact ◽  
What Matters

Abstract Objective To identify what matters to clinicians and patients when discussing cancer medicines’ impact on health-related quality of life (HRQoL). Methods A framework of HRQoL domain/domain elements was developed, informed by analysis of published patient reported outcome measures (PROMs), applicable to prostate cancer. Using mixed methods (eDelphi, Nominal Group Technique and questionnaire), prostate cancer clinicians and patients attending prostate cancer clinics and support groups were asked which domains/domain elements would be important to them when discussing the impact prostate cancer medicines have on their HRQoL. Results Twenty-one clinicians and 71 patients participated from the West of Scotland. Clinicians and patients identified 53/62 domain elements across seven domains as important, of which 32 (60%) were common to both groups. Clinicians placed more importance than patients on Mood & Emotion; in contrast, patients placed importance on a broader range of Symptoms & Side Effects, being informed about their care, and having effective healthcare professional collaboration. Conclusion This study provides insight into the similarities and differences between what clinicians and patients think is important when discussing the impact of cancer medicines on HRQoL. Future research should involve exploring the potential for consistency of medicines PROMs across different cancer types to support patient-clinician communication and drive improvements in care.

scholarly journals The Impact of Enzalutamide on the Prostate Cancer Patient Experience: A Summary Review of Health-Related Quality of Life across Pivotal Clinical Trials

Cancers ◽  
2021 ◽  
Vol 13 (23) ◽  
pp. 5872
Author(s):  
Bertrand Tombal ◽  
Arnulf Stenzl ◽  
David Cella ◽  
Yohann Loriot ◽  
Andrew J. Armstrong ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Prostate Cancer ◽  
Symptom Burden ◽  
Health Related Quality ◽  
Castration Resistant Prostate Cancer ◽  
Castration Resistant ◽  
Related Quality ◽  
Health Related ◽  
The Impact

This review examines the impact of treatment with enzalutamide on health-related quality of life (HRQoL) in prostate cancer patients across the disease continuum based on pivotal clinical trials. We assessed the effect of enzalutamide on pain, symptom burden and overall HRQoL from randomized controlled trials. Patient experience was evaluated in men with metastatic hormone-sensitive prostate cancer (mHSPC), non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic castration-resistant prostate cancer (mCRPC) (pre-chemotherapy and post-chemotherapy). Patients across the disease continuum reported a generally positive status at baseline, with relatively low levels of pain and impairment due to cancer-related symptoms and high HRQoL. For patients with earlier-state prostate cancer, pain and symptom-related burden were low at study entry and remained so, regardless of whether patients received enzalutamide or control treatment. Patients with more advanced disease reported mitigation in pain and symptom burden while receiving treatment with enzalutamide. Enzalutamide was observed to slow deterioration of overall HRQoL most for patients with nmCRPC or mCRPC (statistical significance for between-group difference in median time to deterioration: mHSPC (confirmed) p = 0.2998; nmCRPC (confirmed) p = 0.0044; mCRPC (unconfirmed) p < 0.0001). Across the prostate cancer continuum, enzalutamide is well-tolerated and delays the negative impact that disease progression has on quality of life.

The impact of gastrointestinal and genitourinary toxicity on health related quality of life among irradiated prostate cancer patients

2014 ◽  
Vol 110 (2) ◽  
pp. 284-290 ◽  
Author(s):  
Wouter Schaake ◽  
Erwin M. Wiegman ◽  
Martijn de Groot ◽  
Hans Paul van der Laan ◽  
Cees P. van der Schans ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Prostate Cancer ◽  
Cancer Patients ◽  
Health Related Quality ◽  
Genitourinary Toxicity ◽  
Related Quality ◽  
Health Related ◽  
The Impact

PO-0676 THE IMPACT OF LATE RADIATION-INDUCED TOXICITY ON HEALTH RELATED QUALITY OF LIFE IN PROSTATE CANCER PATIENTS

2012 ◽  
Vol 103 ◽  
pp. S263-S264
Author(s):  
W. Schaake ◽  
E.M. Wiegman ◽  
M. de Groot ◽  
H.P. van der Laan ◽  
J.A. Langendijk ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Prostate Cancer ◽  
Cancer Patients ◽  
Health Related Quality ◽  
Related Quality ◽  
Health Related ◽  
Radiation Induced ◽  
The Impact

scholarly journals Health-related quality of life in men with localized prostate cancer treated with radiotherapy: validation of an abbreviated version of the Expanded Prostate Cancer Index Composite for Clinical Practice in Spain

2021 ◽  
Vol 19 (1) ◽  
Author(s):  
Almudena Zapatero ◽  
Xavier Maldonado Pijoan ◽  
Antonio Gómez-Caamaño ◽  
José Pardo Masferrer ◽  
Víctor Macías Hernández ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Prostate Cancer ◽  
Clinical Practice ◽  
Los Angeles ◽  
External Beam Radiotherapy ◽  
Health Related Quality ◽  
Related Quality ◽  
Health Related ◽  
The Impact

Abstract Background Health-related quality of life (HRQoL) is greatly affected by prostate cancer (PCa) and associated treatments. This study aimed to measure the impact of radiotherapy on HRQoL and to further validate the Spanish version of the 16-item Expanded Prostate Cancer Index Composite (EPIC-16) in routine clinical practice. Methods An observational, non-interventional, multicenter study was conducted in Spain with localized PCa patients initiating treatment with external beam radiotherapy (EBRT) or brachytherapy (BQT). Changes from baseline in EPIC-16, University of California-Los Angeles Prostate Cancer Index (UCLA-PCI), and patient-perceived health status were longitudinally assessed at end of radiotherapy (V2) and 90 days thereafter (V3). Psychometric evaluations of the Spanish EPIC-16 were conducted. Results Of 516 patients enrolled, 495 were included in the analysis (EBRT, n = 361; BQT, n = 134). At baseline, mean (standard deviation [SD]) EPIC-16 global scores were 11.9 (7.5) and 10.3 (7.7) for EBRT and BQT patients, respectively; scores increased, i.e., HRQoL worsened, from baseline, by mean (SD) of 6.8 (7.6) at V2 and 2.4 (7.4) at V3 for EBRT and 4.2 (7.6) and 3.9 (8.2) for BQT patients. Changes in Spanish EPIC-16 domains correlated well with urinary, bowel, and sexual UCLA-PCI domains. EPIC-16 showed good internal consistency (Cronbach’s alpha = .84), reliability, and construct validity. Conclusion The Spanish EPIC-16 questionnaire demonstrated sensitivity, strong discriminative properties and reliability, and validity for use in clinical practice. EPIC-16 scores worsened after radiotherapy in different HRQoL domains; however, a strong tendency towards recovery was seen at the 3-month follow-up visit.

Sign in / Sign up

Export Citation Format

Share Document